A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas This is an ASCO Meeting Abstract ...
68Ga-HER2 affibody PET/CT imaging as an option in patients whose HER2 status of any tumor in the body needs to be deciphered. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This ...
In work that opens a new window on fighting cancer while minimizing side effects, researchers have developed the first small molecule that interacts with a cancer-cell-surface “death receptor,” an ...
PHILADELPHIA – A new twist on a decades-old anticancer strategy has shown powerful effects against multiple cancer types in a preclinical study from researchers in the Perelman School of Medicine at ...
University of Pennsylvania researchers investigated death receptor 5 (DR5 or CD262) as a chimeric antigen receptor (CAR) target for solid tumors.
A new twist on a decades-old anticancer strategy has shown powerful effects against multiple cancer types in a preclinical study from researchers in the Perelman School of Medicine at the University ...
A new twist on a decades-old anticancer strategy has shown powerful effects against multiple cancer types in a preclinical study. The experimental approach, which uses tiny capsules called small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results